Karin Holmsten

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: ESMO OPEN. 2025;10(8):105512
Exploring novel genomic biomarkers for response and survival after neoadjuvant chemotherapy and radical cystectomy of muscle-invasive bladder cancer
Holmsten K; De Laere B; Sjodahl G; Lindberg J; Svedman FC; Ostling P; Eriksson P; Liedberg F; Ullen A
Article: UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS. 2025;43(8):467.e21-467.e29
Impact of glucocorticoid treatment and clinical prognostic factors for outcome in patients with advanced urothelial cancer treated with pembrolizumab.
Hjorthén G; Costa Svedman F; Holmsten K; Ullén A
Article: ACTA ONCOLOGICA. 2025;64:42592-379
Rising incidence trends of synchronous prostate and rectal cancers: a population-based study
Edfelt E; Shahrivar M; Holmsten K; Radkiewicz C
Article: JCO PRECISION ONCOLOGY. 2024;8:e2400209
Molecular Subtypes Are Associated With Clinical Benefit in Cisplatin-Treated Metastatic Urothelial Cancer Patients
Holmsten K; Sjodahl G; Abrahamsson J; Bernardo C; Eriksson P; Hoglund M; Liedberg F; Ullen A
Article: RADIATION ONCOLOGY. 2024;19(1):74
Stereotactic body radiation therapy is beneficial for a subgroup of patients with urothelial cancer and solitary metastatic disease: a single institution real-world experience
Svedman FC; Holmsten K; Jawdat F; Hailom W; Alm D; Grozman V; Ullen A
Article: BJU INTERNATIONAL. 2024;133(6):680-689
Protocol of a randomised, controlled trial comparing immediate curative therapy with conservative treatment in men aged ≥75 years with non-metastatic high-risk prostate cancer (SPCG 19/GRand-P)
Loffeler S; Bertilsson H; Mueller C; Aas K; Haugnes HS; Aksnessaether B; Pesonen M; Thon K; Tandstad T; Murtola T; Poulsen MH; Nordstrom T; Vigmostad MN; Ottosson F; Holmsten K; Christiansen O; Slaaen M; Haug ES; Storas AH; Asphaug L; Rannikko A; Brasso K
Article: INTERNATIONAL JOURNAL OF CANCER. 2024;154(1):180-190
Metastasis and recurrence patterns in the molecular subtypes of urothelial bladder cancer
Sjodahl G; Eriksson P; Holmsten K; Abrahamsson J; Hoglund M; Bernardo C; Ullen A; Liedberg F
Article: CLINICAL GENITOURINARY CANCER. 2023;21(6):e438-e448
Treatment Patterns and Efficacy of Chemotherapy After Pembrolizumab in Advanced Urothelial Cancer-a Real-World Study in the pre-Antibody-Drug Conjugate Era
Holmsten K; Eknert J; Ofverholm E; Papantoniou D; Jawdat F; Verbiene I; Laurell A; Janes E; Sandzen J; Wojtyna-Dziedzic E; Lagstam I; Soderkvist K; Svedman FC; Liedberg F; Bruzelius M; Fransson A-S; Kjellstrom S; Omland LH; Pappot H; Ullen A
Journal article: ANNALS OF ONCOLOGY. 2023;34:s1213-s1214
Stereotactic body radiotherapy (SBRT) of patients with oligometastatic urothelial cancer (UC): A single institution experience
Jawdat F; Svedman FC; Holmsten K; Grozman V; Alm D; Hailom WS; Ullen A
Journal article: EUROPEAN UROLOGY. 2023;83:s1689
Associations between bladder cancer molecular subtypes and metastatic sites
Sjodahl G; Eriksson P; Holmsten K; Abrahamsson J; Hoglund M; Bernardo C; Ullen A; Liedberg F
Journal article: IMMUNO-ONCOLOGY AND TECHNOLOGY. 2022;16:100328
217P Characterization of immune cells in the tumor microenvironment of advanced bladder cancer
Flaberg E; Turkki R; Paavolainen L; Krantz D; Välimäki K; Schoonenberg A; Moussaud E; Holmsten K; Svedman FC; Kallioniemi O; Abrahamsson J; Liedberg F; Sjödahl G; Pellinen T; Ullén A; Östling P
Article: MOLECULAR ONCOLOGY. 2022;16(20):3620-3641
Profiling of extracellular vesicles of metastatic urothelial cancer patients to discover protein signatures related to treatment outcome
Viktorsson K; Haag P; Shah C-H; Franzen B; Arapi V; Holmsten K; Sandstrom P; Lewensohn R; Ullen A
Article: EUROPEAN UROLOGY. 2022;81(5):523-532
Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes
Sjodahl G; Abrahamsson J; Holmsten K; Bernardo C; Chebil G; Eriksson P; Johansson I; Kollberg P; Lindh C; Lovgren K; Marzouka N-A; Olsson H; Hoglund M; Ullen A; Liedberg F
Article: BLADDER CANCER. 2021;8(1):71-80
Implications for Efficacy and Safety of Total Dose and Dose-Intensity of Neoadjuvant Gemcitabine-Cisplatin in Muscle-Invasive Bladder Cancer: Three-Week Versus Four-Week Regimen
Holmsten K; Omland LH; Als AB; Agerbaek M; Dohn LH; Lindberg H; Jensen NV; Carus A; Moe M; Hosseini A; Radkiewicz C; Pappot H; Ullen A
Article: EUROPEAN JOURNAL OF CANCER. 2020;127:173-182
Vinflunine/gemcitabine versus carboplatin/gemcitabine as first-line treatment in cisplatin-ineligible patients with advanced urothelial carcinoma: A randomised phase II trial (VINGEM)
Holmsten K; Jensen NV; Mouritsen LS; Jonsson E; Mellnert C; Agerbaek M; Nilsson C; Moe M; Carus A; Ofverholm E; Lahdenpera O; Brandberg Y; Johansson H; Hellstrom M; von der Maase H; Pappot H; Ullen A
Article: ONCOLOGIST. 2019;24(6):745-e213
Safety and Activity of Sorafenib in Addition to Vinflunine in Post-Platinum Metastatic Urothelial Carcinoma (Vinsor): Phase I Trial
Shah C-H; Pappot H; Agerbaek M; Holmsten K; Jaderling F; Yachnin J; Gryback P; von der Maase H; Ullen A
Journal article: EUROPEAN UROLOGY OPEN SCIENCE. 2019;18(1):e2106-e2107
PT325 Pathologic downstaging after neoadjuvant cisplatin-based combination chemotherapy in immunohistochemistry-defined molecular subtypes of bladder cancer
Sjodahl G; Abrahamsson J; Holmsten K; Eriksson P; Lövgren K; Lindh C; Ullén A; Liedberg F
Journal article: EUROPEAN UROLOGY OPEN SCIENCE. 2018;17(14):e3001
P162 Safety and activity of sorafenib in addition to vinflunine in post-platinum metastatic urothelial carcinoma (Vinsor): Phase I trial
Shah C-H; Pappot H; Agerbæk M; Holmsten K; Jäderling F; Yachnin J; Grybäck P; Von Der Maase H; Ullén A
Journal article: EUROPEAN UROLOGY OPEN SCIENCE. 2017;16(10):e2797
P145 A multicenter, randomized phase II trial of vinflunine and gemcitabine versus carboplatin and gemcitabine as first line treatment in patients with metastatic urothelial carcinoma unfit for cisplatin based chemotherapy due to impaired renal function-VINGEM
Holmsten K; Jensen NV; Mouritsen LS; Agerbæk M; Kempel MM; Trepkas R; Lahdenperä O; Öfverholm E; Mellnert C; Cwikiel M; Jonsson E; Nilsson C; Shah C-H; Johansson H; Brandberg Y; Von Der Maase H; Pappot H; Ullén A
Article: ONCOLOGY LETTERS. 2016;12(2):1293-1300
Vinflunine treatment in patients with metastatic urothelial cancer: A Nordic retrospective multicenter analysis
Holmsten K; Dohn LH; Jensen NV; Shah C-H; Jaderling F; Pappot H; Ullen A
Article: MOLECULAR ONCOLOGY. 2016;10(5):719-734
Melphalan-flufenamide is cytotoxic and potentiates treatment with chemotherapy and the Src inhibitor dasatinib in urothelial carcinoma
Viktorsson K; Shah C-H; Juntti T; Haag P; Zielinska-Chomej K; Sierakowiak A; Holmsten K; Tu J; Spira J; Kanter L; Lewensohn R; Ullen A
Journal article: EUROPEAN UROLOGY OPEN SCIENCE. 2013;12(6):136-137
P017 Vinflunine as second line chemotherapy for patients with metastatic urothelial cancer – A Nordic multi-center retrospective study
Holmsten K; Dohn LH; Jensen NV; Shah C-H; Pappot H; Ullén A; Group NUCO
Visa fler

Alla övriga publikationer

Preprint: RESEARCH SQUARE. 2024
Stereotactic body radiation therapy is beneficial for a subgroup of patients with urothelial cancer and solitary metastatic disease: a single institution real-world experience
Svedman FC; Holmsten K; Jawdat F; Hailom W; Alm D; Grozman V; Ullén A
Letter: ACTA ONCOLOGICA. 2022;61(12):1515-1516
The optimal neoadjuvant chemotherapy regime for muscle-invasive bladder cancer: still an open question?
Carus A; Holmsten K; Pappot H; Ullen A
Letter: EUROPEAN UROLOGY. 2022;81(4):e92-e93
Reply to Joep J. de Jong and Ewan A. Gibb's Letter to the Editor re: Gottfrid Sjodahl, Johan Abrahamsson, Karin Holmsten, et al. Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes. Eur Urol. 2022;81:316-7. Neoadjuvant Chemotherapy Response in Muscle-invasive Bladder Cancer: Differences in Intrinsic Biology or Subtyping Nomenclature?
Sjodahl G; Abrahamsson J; Holmsten K; Bernardo C; Eriksson P; Kollberg P; Marzouka N-A; Hoglund M; Ullen A; Liedberg F
Preprint: MEDRXIV. 2021
Different responses to neoadjuvant chemotherapy in urothelial carcinoma molecular subtypes
Sjödahl G; Abrahamsson J; Holmsten K; Bernardo C; Chebil G; Eriksson P; Johansson I; Kollberg P; Lindh C; Lövgren K; Marzouka N-A; Olsson H; Höglund M; Ullén A; Liedberg F
Doctoral thesis: 2020
Improving chemotherapy in advanced urothelial cancer : real-world data studies and prospective clinical trials
Holmsten K
Corrigendum: ONCOLOGY LETTERS. 2017;13(6):5035
Vinflunine treatment in patients with metastatic urothelial cancer: A Nordic retrospective multicenter analysis (vol 12, pg 1293, 2016)
Holmsten K; Dohn L; Jensen NV; Shah C-H; Jaderling F; Pappot H; Ullen A

Anställningar

Anknuten till Forskning, Onkologi-Patologi, Karolinska Institutet, 2024-2025

Examina och utbildning

Medicine Doktorsexamen, Institutionen för onkologi-patologi, Karolinska Institutet, 2020

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI